Literature DB >> 12603341

Effects of five commonly used glucocorticoids on haemangioma in vitro.

Q Hasan1, S T Tan, B Xu, P F Davis.   

Abstract

1. High-dose systemic or intralesional steroids are the first-line pharmacological treatments for haemangioma. However, the mechanism of action of steroids is unknown. Using the in vitro model developed by us, the present study examined some of the effects of five commonly used glucocorticoids on haemangioma biopsies taken from two patients. 2. At 12 micro mol/L, triamcinolone and dexamethasone consistently exhibited capillary growth inhibition, whereas methylprednisolone displayed an inhibitory effect during the first 7 days of culture. At this concentration, inhibition of capillary growth was observed in betamethasone-treated cultures derived from one patient but not in those derived from the other. However, hydrocortisone had a negligible effect on capillary growth. 3. Transcription of various factors considered important for haemangioma development were studied by reverse transcription-polymerase chain reaction. Neither vascular endothelial growth factor nor fibroblast growth factor-2 played a vital role in steroid-induced inhibition of capillary growth. All glucocorticoids induced a marked decrease of interleukin (IL)-6 transcripts. 4. Capillary growth inhibition in cultures treated with all glucocorticoids, except triamcinolone, was associated with an increased transcription of clusterin/apolipoprotein J (clust/apoJ), an apoptotic gene. There was increased transcription of mitochondrial cytochrome (cyt) b in the inhibited cultures resulting from triamcinolone, dexamethasone or methylprednisolone treatment that was associated with capillary growth inhibition, suggesting an important role of mitochondria in glucocorticoid-induced regression of haemangioma. 5. Our results indicate that glucocorticoids may modulate haemangiogenesis via an upregulation of cyt b, clust/apoJ and/or IL-6. The variable effects of different glucocorticoids on one or more of these factors may explain the interindividual variation in the in vivo response of haemangioma to the steroids.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12603341     DOI: 10.1046/j.1440-1681.2003.03815.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  11 in total

Review 1.  Infantile hemangioma-mechanism(s) of drug action on a vascular tumor.

Authors:  Shoshana Greenberger; Joyce Bischoff
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

2.  Successful treatment of Kasabach-Merritt syndrome arising from kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery.

Authors:  Run-song Jiang; Rong Hu
Journal:  Int J Clin Oncol       Date:  2011-09-28       Impact factor: 3.402

3.  Evaluating systemic prednisone therapy for proliferating haemangioma in infancy.

Authors:  Jochen Rössler; Goetz Wehl; Charlotte Marie Niemeyer
Journal:  Eur J Pediatr       Date:  2007-08-04       Impact factor: 3.183

4.  Myeloid cells in infantile hemangioma.

Authors:  Matthew R Ritter; John Reinisch; Sheila Fallon Friedlander; Martin Friedlander
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

5.  Differential modulation of glucocorticoid action by FK506 in A549 cells.

Authors:  Jamie D Croxtall; Mark Paul-Clark; Peter Th W Van Hal
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

6.  Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells.

Authors:  Shoshana Greenberger; Elisa Boscolo; Irit Adini; John B Mulliken; Joyce Bischoff
Journal:  N Engl J Med       Date:  2010-03-18       Impact factor: 91.245

7.  Treating subglottic haemangioma with methylprednisolone and interferonα-2a.

Authors:  Suprabha Kumari Patnaik; Vishal Sondhi
Journal:  BMJ Case Rep       Date:  2009-04-07

Review 8.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

9.  The synergistic effect of bleomycin, triamcinolone and epinephrine in treatment of hemangioma and arteriovenous malformations.

Authors:  Hamid Masiha; Heydar Ali Nikpour; Mohammad Esmaeil Hasani; Abolhasan Emami; Mehryar Jafari; Ali Manafi
Journal:  World J Plast Surg       Date:  2012-07

10.  Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity.

Authors:  Maximino Redondo; Teresa Téllez; Maria J Roldan; Alfonso Serrano; Maria García-Aranda; Martin E Gleave; Maria L Hortas; Miguel Morell
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.